Table 2 Visit-to-visit (clinic) blood pressure variability outcomes.

From: Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST

BP parameter

Placebo

Allopurinol

Unadjusted between group difference

P value

Adjusted between group difference

P value

n = 204,

n = 205,

(95% CI)

(95% CI)

mean ± SD

mean ± SD

  

SBPMean (mmHg)

137.4 ± 12.4

135.7 ± 13.0

1.71 (–0.76, 4.17)

0.174

  

SBPRange (mmHg)

30.5 ± 14.0

30.7 ± 13.1

–0.18 (–2.82, 2.46)

0.893

–0.86 (–3.31, 1.60)

0.494

SBPSD (mmHg)

11.5 ± 5.3

11.7 ± 5.0

–0.12 (–1.12, 0.88)

0.808

–0.38 (–1.31, 0.53)

0.424

SBPARV (mmHg)

12.7 ± 6.2

12.9 ± 6.0

–0.20 (–1.40, 0.99)

0.746

–0.46 (–1.59, 0.69)

0.423

SBPCV (%)

8.3 ± 3.6

8.5 ± 3.4

–0.20 (–0.88, 0.48)

0.562

–0.28 (–0.96, 0.39)

0.407

SBPVIM (units)

11.3 ± 4.8

11.7 ± 4.6

–0.40 (–1.31, 0.52)

0.398

–0.41 (–1.33, 0.52)

0.387

DBPMean (mmHg)

79.9 ± 7.9

79.1 ± 7.6

0.79 (–0.72, 2.29)

0.305

  

DBPRange (mmHg)

18.4 ± 8.3

18.3 ± 7.6

0.14 (–1.41, 1.68)

0.863

0.05 (–1.49, 1.60)

0.946

DBPSD (mmHg)

7.0 ± 3.1

6.9 ± 2.8

0.05 (–0.52, 0.62)

0.862

0.02 (–0.54, 0.59)

0.934

DBPARV (mmHg)

7.8 ± 3.8

7.9 ± 3.4

–0.15 (–0.85, 0.54)

0.663

–0.18 (–0.88, 0.51)

0.601

DBPCV (%)

8.8 ± 3.9

8.8 ± 3.6

–0.01 (–0.74, 0.72)

0.977

0.04 (–0.68, 0.77)

0.905

DBPVIM (units)

7.0 ± 3.1

6.9 ± 2.8

0.03 (–0.54, 0.60)

0.923

0.03 (–0.54, 0.60)

0.922

  1. N = 409. Differences are given as placebo subtract allopurinol (a positive difference denotes a change in favor of allopurinol). Analyses were adjusted for on-treatment mean systolic or diastolic BP.
  2. BP Blood Pressure, SBP Systolic BP, DBP Diastolic BP, n number, SD Standard Deviation, CI Confidence Interval, ARV Average Real Variability, CV Coefficient of Variation, VIM Variation Independent of Mean.
Back to article page